A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants

Trial Profile

A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.
    • 10 Jun 2017 Biomarkers information updated
    • 03 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top